Format

Send to

Choose Destination
See comment in PubMed Commons below
Innov Clin Neurosci. 2012 Mar;9(3):17-8.

Trends in combination antipsychotic use among persons with commercial insurance: a data snapshot.

Author information

  • 1Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York, USA. nntman@gmail.com

Abstract

In this data snapshot, the IMS PharMetrics Database was examined to assess the prevalence of combination antipsychotic therapy for the years 2003 through 2009 among 122,349 commercially insured adult individuals with bipolar disorder, depression, or schizophrenia. Although all three diagnostic groups were associated with varying amounts of combination antipsychotic use that included aripiprazole, olanzapine, quetiapine, risperidone and ziprasidone, persons with schizophrenia exhibited the highest rates. These findings indicate that from the perspective of "practice-based evidence," providers see value in combination therapy.

KEYWORDS:

Antipsychotic; bipolar disorder; combination therapy; commercially insured; depression; outpatient; schizophrenia

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk